Eli Lilly and Company (BIT:1LLY)

Market Cap	771.20B +11.3%
Revenue (ttm)	55.51B +44.7%
Net Income	17.58B +94.9%
EPS	19.55 +96.0%
Shares Out	n/a
PE Ratio	43.87
Forward PE	29.51
Dividend	5.36 (0.62%)
Ex-Dividend Date	Nov 13, 2025

Volume	14
Average Volume	632
Open	866.60
Previous Close	869.60
Day's Range	862.00 - 866.60
52-Week Range	535.20 - 972.00
Beta	n/a
RSI	45.58
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LLY

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD